FOXP3 and inflammatory bowel disease: Based on this feature, several probiotics and the PSA of B. fragilis have been used to inhibit the progression of inflammation through the upregulation of Foxp3+ Tregs and to promote the immunotherapy of IBD (70) or the HIV-1 infection (67).